Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs Brainstorm Cell Therapeutics Inc. (BCLI)

AIM ImmunoTech Inc. and Brainstorm Cell Therapeutics Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Brainstorm Cell Therapeutics Inc. are of similar size ($7.0M and $6.8M). Brainstorm Cell Therapeutics Inc. has the higher net margin (0.00% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Brainstorm Cell Therapeutics Inc. leads on 9 and AIM ImmunoTech Inc. on 3.

Valuation

Metric AIM BCLI Biotechnology median
P/E n/m n/m 8.50
P/S 30.63 n/m 9.71
P/B 0.38 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.69 n/m 0.64
EV/Sales (69.58) n/m 9.21
Earnings yield (1,718.41%) (119.40%) (33.15%)
Free cash flow yield (502.43%) (47.20%) (25.50%)

Profitability

Metric AIM BCLI Biotechnology median
Gross margin (23.16%) 0.00% 65.16%
Operating margin (11,724.21%) 0.00% 0.00%
Net margin (15,021.05%) 0.00% 0.00%
Free cash flow margin (15,385.26%) 0.00% 0.00%
Return on equity (2,382.30%) 119.20% (56.36%)
Return on assets (169.28%) (627.43%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM BCLI Biotechnology median
Revenue growth (TTM) (21.49%) — 6.02%
EPS growth (last fiscal year) 72.19% 51.95% 30.26%
Revenue growth, 5-year CAGR (11.60%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM BCLI Biotechnology median
Debt to equity 0.00 (0.11) 0.00
Current ratio 2.11 0.03 4.72
Net debt to EBITDA 0.22 (0.10) 0.96

Dividend

Metric AIM BCLI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AIM BCLI Biotechnology median
Market cap 6.79m 6.99m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack